Kura Oncology, Inc. KURA
Set alert
10.26 USD -0.30 -2.84%
At close · Oct 30
10.26 0.00 0.00%
After hours · Oct 30, 4:33 PM ET
9.94 Day range 10.75
7.40 52-week range 13.59
- YTD
- -1.25%
- 1 year
- -1.72%
- Open
- 10.50
- Prev close
- 10.56
- Mkt cap
- 912.74M
- Vol
- 2.25M
- Avg vol
- 1.87M
- EPS
- -3.37
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.94
- High
- 10.75
- Forward P/E
- -5.11
- Beta
- 0.43
- Short ratio
- 6.19
- Inst. own
- 99.74%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 11.17
- 200-d avg
- 9.82
- 1y target
- 32.00
Key statistics
- Market cap
- 1.04B
- Enterprise value
- 537.37M
- Trailing P/E
- 0.00
- Forward P/E
- -5.11
- PEG ratio
- 0.00
- Price / sales
- 13.51
- Price / book
- 21.56
- EPS (TTM)
- -3.37
- Beta
- 0.43
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 77.22M
- Revenue growth
- 36.50%
- Free cash flow
- -165.88M
- Total cash
- 519.02M
- Total debt
- 24.45M
- Return on equity
- -167.71%
- Shares outstanding
- 88.96M
- Short % of float
- 15.48%
- 50-day average
- 11.17
- 200-day average
- 9.82
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 32.00 +211.9% upside
Now 10.26
- Target (low)
- 15.00
- Target (mean)
- 32.00
- Target (high)
- 76.00
Ratings (0m) 15 14 buy · 1 hold · 0 sell
- Strong buy2
- Buy12
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate -0.80667.
Financials — quick view
KURA Revenue — quarterly 20.87M
KURA Net income — quarterly -68.33M
KURA EPS — quarterly -0.77
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -0.84 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | -0.87733 | -0.77 | +0.11 | +12.23% |
| May 12, 2026 | Mar 31, 2026 | -0.88 | -0.83 | +0.05 | +5.68% |
| Mar 5, 2026 | Dec 31, 2025 | -0.72 | -0.92 | -0.20 | -27.78% |
| Nov 4, 2025 | Sep 30, 2025 | -0.57 | -0.85 | -0.28 | -49.12% |
| Aug 7, 2025 | Jun 30, 2025 | 0.15 | -0.75 | -0.90 | -600.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 24, 2026 | Citizens | reit | Market Outperform | Market Outperform |
| Aug 13, 2026 | Wedbush | main | Outperform | Outperform |
| Jul 28, 2026 | Wedbush | reit | Outperform | Outperform |
| Jun 15, 2026 | Citizens | reit | Market Outperform | Market Outperform |
| Apr 14, 2026 | Lake Street | init | — | Buy |
| Mar 24, 2026 | Mizuho | main | Outperform | Outperform |
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kuraoncology.com
News
- Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know
- Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor
- Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript
- Caspian Therapeutics, Kura Oncology Plan To Devise Development Strategy For Caspian's KO-7246 Oral Menin Inhibitor Designed For Diabetes And Other Chronic Metabolic Diseases
- Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes
- Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in Diabetes
- Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- This Toll Brothers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
- JP Morgan Initiates Coverage On Kura Oncology with Overweight Rating, Announces Price Target of $30
- Caspian Therapeutics And Kura Oncology Released Comprehensive Preclinical Data Supporting KO-7246 For Diabetes
Your note
Sign in to keep a note on KURA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAIR TERESA BROPHY | Officer | Sale | Aug 18, 2026 | 195,444 |
| BURROWS FRANCIS J. PH.D. | Officer | Sale | Jan 26, 2026 | 32,424 |
| DOYLE THOMAS JAMES | Officer | Sale | Jan 26, 2026 | 145,667 |
| FORD KATHLEEN | Chief Operating Officer | Sale | May 18, 2026 | 153,560 |
| HASNAIN FAHEEM | Director | Conversion of Exercise of derivative security | Dec 8, 2025 | 23,983 |
| LEONI MOLLIE M.D. | Officer | Sale | Jun 17, 2026 | 182,345 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 11.81% | 10,509,233 | 123.27M | Jun 29, 2026 |
| Montanova Capital LLC | 9.64% | 8,575,422 | 100.59M | Jun 29, 2026 |
| BVF Inc. | 9.49% | 8,445,769 | 99.07M | Jun 29, 2026 |
| State Street Corporation | 5.99% | 5,329,208 | 62.51M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.40% | 3,916,164 | 45.94M | Jun 29, 2026 |
| Armistice Capital, LLC | 4.13% | 3,678,000 | 43.14M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.40% | 3,020,727 | 35.43M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.15% | 2,799,338 | 32.84M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.44% | 2,168,959 | 25.44M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.15% | 1,026,943 | 12.05M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.04% | 921,604 | 10.81M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.88% | 780,455 | 9.15M | Jul 30, 2026 |